Faruqi & Faruqi Investigates Securities Fraud Claims Against Aquestive
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy AQST?
Source: Globenewswire
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud claims against Aquestive Therapeutics, Inc. for actions between June 16, 2025, and January 8, 2026, urging investors to seek lead plaintiff status in a class action by the May 4, 2026 deadline.
- Stock Price Plunge: On January 9, 2026, Aquestive's stock fell by $2.30, or 37.04%, closing at $3.91 per share after the FDA identified deficiencies in its NDA, reflecting market concerns over the company's compliance and future outlook.
- False Statement Allegations: The complaint alleges that Aquestive and its executives violated federal securities laws by failing to disclose the true state of its NDA for Anaphylm, particularly concealing human factors, which could lead to significant investor losses.
- Investor Rights Protection: Faruq & Faruqi encourages affected investors to contact the firm directly to ensure their legal rights are protected, while also inviting whistleblowers and others with information to participate in the investigation, demonstrating a commitment to safeguarding investor interests.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AQST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AQST
Wall Street analysts forecast AQST stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.880
Low
6.00
Averages
9.00
High
12.00
Current: 3.880
Low
6.00
Averages
9.00
High
12.00
About AQST
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Faruqi & Faruqi Investigates Securities Fraud Claims Against Aquestive
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud claims against Aquestive Therapeutics, Inc. for actions between June 16, 2025, and January 8, 2026, urging investors to seek lead plaintiff status in a class action by the May 4, 2026 deadline.
- Stock Price Plunge: On January 9, 2026, Aquestive's stock fell by $2.30, or 37.04%, closing at $3.91 per share after the FDA identified deficiencies in its NDA, reflecting market concerns over the company's compliance and future outlook.
- False Statement Allegations: The complaint alleges that Aquestive and its executives violated federal securities laws by failing to disclose the true state of its NDA for Anaphylm, particularly concealing human factors, which could lead to significant investor losses.
- Investor Rights Protection: Faruq & Faruqi encourages affected investors to contact the firm directly to ensure their legal rights are protected, while also inviting whistleblowers and others with information to participate in the investigation, demonstrating a commitment to safeguarding investor interests.
See More
Class Action Lawsuit Filed Against Aquestive Therapeutics
- Class Action Initiation: Pomerantz LLP has announced a class action lawsuit against Aquestive Therapeutics, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors needing to apply by May 4, 2026, to become Lead Plaintiff, which could significantly impact the company's reputation and shareholder confidence.
- FDA Review Delay: On January 9, 2026, Aquestive received a letter from the FDA identifying deficiencies in its New Drug Application for Anaphylm, preventing labeling discussions and effectively delaying approval indefinitely, which may adversely affect the company's future revenue projections.
- Significant Stock Price Drop: Following the FDA news, Aquestive's stock price fell by $2.30, or 37.04%, closing at $3.91 per share, reflecting a pessimistic market sentiment regarding the company's outlook and potentially leading to further erosion of investor confidence.
- Legal Background: Pomerantz LLP is a prominent law firm specializing in securities class action litigation, founded over 85 years ago to advocate for victims of securities fraud and corporate misconduct, and this lawsuit may provide compensation opportunities for affected investors, highlighting the importance of legal frameworks in maintaining market integrity.
See More
Shareholder Notice for Aquestive Therapeutics Class Action
- Shareholder Alert: The Gross Law Firm has issued a notice to shareholders who purchased AQST shares between June 16, 2025, and January 8, 2026, encouraging them to contact the firm for potential lead plaintiff appointment, ensuring participation in any recovery from the class action.
- FDA Regulatory Deficiencies: On January 9, 2026, Aquestive announced receipt of a letter from the FDA identifying deficiencies in its New Drug Application for Anaphylm, which precluded labeling discussions and delayed approval beyond the January 31, 2026 deadline, negatively impacting the company's market outlook.
- Stock Price Plunge: Following the FDA's notification, AQST's stock price plummeted from $6.21 per share on January 8, 2026, to $3.91 per share on January 9, representing a dramatic decline of over 37% in a single day, reflecting market pessimism regarding the company's future.
- Class Action Deadline: Shareholders must register for the class action by May 4, 2026, and upon registration, they will receive real-time updates on the case's progress, ensuring that shareholders do not lose their rights in the legal proceedings.
See More
Class Action Reminder for Aquestive Investors
- Lawsuit Background: Robbins LLP reminds all investors who purchased or acquired Aquestive Therapeutics, Inc. (NASDAQ:AQST) securities between June 16, 2025, and January 8, 2026, that a class action has been filed, alleging the company misled investors regarding the approval status of its drug Anaphylm.
- FDA Feedback: During the class period, the FDA identified deficiencies in the company's New Drug Application (NDA) for Anaphylm, preventing labeling discussions and post-marketing commitments, which delayed the drug's launch and indicated that the company failed to secure approval by the January 31, 2026 PDUFA date.
- Stock Price Impact: On January 9, 2026, Aquestive announced it received a letter from the FDA confirming that its NDA review was ongoing and no final decision had been made, causing the stock price to plummet over 37% from $6.21 per share on January 8, 2026, to $3.91 per share, reflecting market pessimism about the company's prospects.
- Shareholder Action: Shareholders can submit their papers by May 4, 2026, to apply as lead plaintiffs in the class action, representing other shareholders in the litigation, and they do not need to participate in the case to be eligible for recovery, highlighting potential governance issues within the company and the growing awareness among investors for their rights.
See More
Rosen Law Firm Reminds of Aquestive Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ:AQST) securities between June 16, 2025, and January 8, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as attorney fees will be covered through a contingency fee arrangement, significantly lowering the financial barrier for participation in the lawsuit and encouraging more investors to seek legal recourse.
- Lawsuit Background: The lawsuit alleges that Aquestive made false or misleading statements regarding its New Drug Application, failing to disclose critical human factors in the use of its sublingual film, which resulted in investor losses when the truth emerged, highlighting significant issues in the company's transparency and compliance.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and effectiveness in handling such cases.
See More
Class Action Notice for Aquestive Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ: AQST) securities between June 16, 2025, and January 8, 2026, that the important lead plaintiff deadline is May 4, 2026, allowing potential compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that defendants made false and/or misleading statements and failed to disclose the true state of the New Drug Application (NDA) for Anaphylm, resulting in investor losses when the truth emerged, highlighting a lack of transparency in the company's drug development process.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its strong capabilities and successful track record in this field.
- Participation Instructions: Investors can join the class action by visiting Rosen Law Firm's website or calling toll-free at 866-767-3653, and those wishing to serve as lead plaintiffs must file with the court by May 4, 2026, ensuring their representation in the litigation.
See More
Faruqi & Faruqi Investigates Securities Fraud Claims Against Aquestive
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud claims against Aquestive Therapeutics, Inc. for actions between June 16, 2025, and January 8, 2026, urging investors to seek lead plaintiff status in a class action by the May 4, 2026 deadline.
- Stock Price Plunge: On January 9, 2026, Aquestive's stock fell by $2.30, or 37.04%, closing at $3.91 per share after the FDA identified deficiencies in its NDA, reflecting market concerns over the company's compliance and future outlook.
- False Statement Allegations: The complaint alleges that Aquestive and its executives violated federal securities laws by failing to disclose the true state of its NDA for Anaphylm, particularly concealing human factors, which could lead to significant investor losses.
- Investor Rights Protection: Faruq & Faruqi encourages affected investors to contact the firm directly to ensure their legal rights are protected, while also inviting whistleblowers and others with information to participate in the investigation, demonstrating a commitment to safeguarding investor interests.
See More
Class Action Lawsuit Filed Against Aquestive Therapeutics
- Class Action Initiation: Pomerantz LLP has announced a class action lawsuit against Aquestive Therapeutics, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors needing to apply by May 4, 2026, to become Lead Plaintiff, which could significantly impact the company's reputation and shareholder confidence.
- FDA Review Delay: On January 9, 2026, Aquestive received a letter from the FDA identifying deficiencies in its New Drug Application for Anaphylm, preventing labeling discussions and effectively delaying approval indefinitely, which may adversely affect the company's future revenue projections.
- Significant Stock Price Drop: Following the FDA news, Aquestive's stock price fell by $2.30, or 37.04%, closing at $3.91 per share, reflecting a pessimistic market sentiment regarding the company's outlook and potentially leading to further erosion of investor confidence.
- Legal Background: Pomerantz LLP is a prominent law firm specializing in securities class action litigation, founded over 85 years ago to advocate for victims of securities fraud and corporate misconduct, and this lawsuit may provide compensation opportunities for affected investors, highlighting the importance of legal frameworks in maintaining market integrity.
See More
Shareholder Notice for Aquestive Therapeutics Class Action
- Shareholder Alert: The Gross Law Firm has issued a notice to shareholders who purchased AQST shares between June 16, 2025, and January 8, 2026, encouraging them to contact the firm for potential lead plaintiff appointment, ensuring participation in any recovery from the class action.
- FDA Regulatory Deficiencies: On January 9, 2026, Aquestive announced receipt of a letter from the FDA identifying deficiencies in its New Drug Application for Anaphylm, which precluded labeling discussions and delayed approval beyond the January 31, 2026 deadline, negatively impacting the company's market outlook.
- Stock Price Plunge: Following the FDA's notification, AQST's stock price plummeted from $6.21 per share on January 8, 2026, to $3.91 per share on January 9, representing a dramatic decline of over 37% in a single day, reflecting market pessimism regarding the company's future.
- Class Action Deadline: Shareholders must register for the class action by May 4, 2026, and upon registration, they will receive real-time updates on the case's progress, ensuring that shareholders do not lose their rights in the legal proceedings.
See More
Class Action Reminder for Aquestive Investors
- Lawsuit Background: Robbins LLP reminds all investors who purchased or acquired Aquestive Therapeutics, Inc. (NASDAQ:AQST) securities between June 16, 2025, and January 8, 2026, that a class action has been filed, alleging the company misled investors regarding the approval status of its drug Anaphylm.
- FDA Feedback: During the class period, the FDA identified deficiencies in the company's New Drug Application (NDA) for Anaphylm, preventing labeling discussions and post-marketing commitments, which delayed the drug's launch and indicated that the company failed to secure approval by the January 31, 2026 PDUFA date.
- Stock Price Impact: On January 9, 2026, Aquestive announced it received a letter from the FDA confirming that its NDA review was ongoing and no final decision had been made, causing the stock price to plummet over 37% from $6.21 per share on January 8, 2026, to $3.91 per share, reflecting market pessimism about the company's prospects.
- Shareholder Action: Shareholders can submit their papers by May 4, 2026, to apply as lead plaintiffs in the class action, representing other shareholders in the litigation, and they do not need to participate in the case to be eligible for recovery, highlighting potential governance issues within the company and the growing awareness among investors for their rights.
See More
Rosen Law Firm Reminds of Aquestive Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ:AQST) securities between June 16, 2025, and January 8, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as attorney fees will be covered through a contingency fee arrangement, significantly lowering the financial barrier for participation in the lawsuit and encouraging more investors to seek legal recourse.
- Lawsuit Background: The lawsuit alleges that Aquestive made false or misleading statements regarding its New Drug Application, failing to disclose critical human factors in the use of its sublingual film, which resulted in investor losses when the truth emerged, highlighting significant issues in the company's transparency and compliance.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and effectiveness in handling such cases.
See More
Class Action Notice for Aquestive Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ: AQST) securities between June 16, 2025, and January 8, 2026, that the important lead plaintiff deadline is May 4, 2026, allowing potential compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that defendants made false and/or misleading statements and failed to disclose the true state of the New Drug Application (NDA) for Anaphylm, resulting in investor losses when the truth emerged, highlighting a lack of transparency in the company's drug development process.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its strong capabilities and successful track record in this field.
- Participation Instructions: Investors can join the class action by visiting Rosen Law Firm's website or calling toll-free at 866-767-3653, and those wishing to serve as lead plaintiffs must file with the court by May 4, 2026, ensuring their representation in the litigation.
See More
